Artiva Biotherapeutics, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-11-17 reports Item 5.02 event (departure of directors/officers and compensatory arrangements) with period of report 2026-11-11. The actual text of the compensatory arrangements and officer departure details is not disclosed in the filing header provided — only the item category is indicated. No specific names, amounts, dates, or terms are available in the document excerpt.
Why this rating
Cannot assess magnitude without actual disclosure details. Officer changes are routine for $15M-cap biotech unless C-suite departure or massive severance. Text redacted/unavailable.
Extracted items
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.